Founded in 2017, Nalo’s mission is to address unmet needs in cancer by developing therapeutics targeting oncogenic driver mutations and/or proteins that are well-known but often hard to drug.
In collaboration with our UCSF scientific cofounders, Nalo set out to tackle one of the most challenging and well know drug targets in oncology: the Myc oncoprotein. Utilizing new insights into the biology of the Myc protein and its’ regulation by the cell, Nalo has developed small molecules that induce the natural degradation of the Myc protein that leads to cancer cell apoptosis.
To expand our pipeline, in 2021, Nalo acquired a clinical-ready small molecule asset, a next generation brain-penetrant EGFR inhibitor, NX-019, to address significant unmet needs in EGFR mutant Non-Small Cell Lung Cancer (NSCLC). NX-019 is designed to selectively spare wild-type EGFR and efficiently cross the blood brain barrier (BBB). NX-019 is now in a FIH clinical study in NSCLC in the US and Asia.
Keith Wilson, PhD
Founder, President & CSO
Stephen Shuttleworth, PhD
Rachel Dusek, PhD
VP Translational Medicine
Cory Freedland, PhD
David Parry, PhD
Srini Akkaraju, MD, PhD
NX‑201 – a novel small molecule approach to targeted Myc degradation
Nalo has tackled one of the best-known disease drivers in cancer: the Myc transcription factor. Leveraging insights and expertise from our scientific founders at the University of California, San Francisco, we have rationally designed molecules that target the Myc protein, shutting off the cellular programming that leads to cancer progression. Clinical trials for these molecules are in preparation.
Journey with us
Nalo Therapeutics is a highly integrated and diverse team of experienced individuals with comprehensive skills in basic research, medicinal chemistry, pre-clinical and clinical development. We are committed to continuing to build a dynamic and collaborative team of exceptional and dedicated professionals working with a passion to make quick impacts and deliver truly effective medicines to cancer patients with high unmet needs.
We currently do not have any open positions. If you are interested in learning more about Nalo Therapeutics and potential future positions, please contact us at email@example.com.